Cite
HARVARD Citation
Smith, P. et al. (2017). A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. British journal of clinical pharmacology. pp. 2367-2376. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Smith, P. et al. (2017). A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers. British journal of clinical pharmacology. pp. 2367-2376. [Online].